喜炎平联合奥司他韦治疗流行性感冒Meta分析

A Meta Analysis of Xiyanping Injection Combined with Oseltamivir in the Treatment of Influenza

目的:评价喜炎平注射液联合奥司他韦较单用奥司他韦治疗流行性感冒的临床疗效及安全性。方法:检索国内外数据库中关于喜炎平联合奥司他韦治疗流行性感冒的随机对照试验(randomized controlled trial,RCTs),检索时限为自建库至2019年1月。筛选合格文献,进行质量评价及Meta分析。结果:共纳入5篇RCTs,包含316例患者。Meta分析结果显示,与单用奥司他韦组比较,喜炎平联合奥司他韦组在总有效率(OR=4.69,95%CI [2.69,11.09],P <0.01),减少退热时间(MD=4.83,95%CI[-1.73,-0.73],P <0.01)和住院时间(MD=6.33,95%CI [-2.63,-1.39],P <0.01)方面更具优势;在不良反应方面,2组差异无统计学意义(P> 0.5)。结论:喜炎平联合奥司他韦治疗流行性感冒的临床疗效优于单用奥司他韦,且安全性良好。

Objective:To evaluate the clinical effect and safety of Xiyanping injection combined with oseltamivir in the treatment of influenza.Methods:The randomized controlled trials(RCTs)on the treatment of influenza with Xiyanping combined with oseltamivir in the databases at home and abroad were retrieved.The retrieval time was from the database established day to January 2019.Qualified literatures were selected for quality evaluation and Meta analysis.Results:A total of 5 RCTs were included,including 316 patients.Results of Meta analysis showed that compared with the pure oseltamivir group,the xiyanping combined with oseltamivir group had more advantages in the total effective rate(OR=4.69,95%CI[2.69,11.09],P<0.01),antipyretic-reducing duration(MD=4.83,95%CI[-1.73,-0.73],P<0.01)and the hospitalization duration(MD=6.33,95%CI[-2.63,-1.39],P<0.01).In terms of adverse reactions,there was no statistically significant difference between the two groups(P>0.5).Conclusion:Xiyanping injection combined with oseltamivir in the treatment of influenza has better clinical effect than oseltamivir alone and has good safety.